Category: Allies & Partnerships
SPORE Grants: Putting Collaboration Front & Center
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 24 September 2019 In Allies & Partnerships, Science, Treatment
In medicine, sometimes the biggest and most game-changing advancements come from a single person – who through tireless work – arrives at a true ‘eureka’ moment. This ‘go it alone’ concept is not only reinforced through television and movies, it’s also bolstered in the way the medical community makes research...
Treating Melanoma Patients Before Surgery
Over 90% of patients who have their tumors surgically removed will never see their tumors come back or spread to other sites, but is there a way to prevent recurrence in those patients that will eventually go on to relapse? One approach currently being tested in clinical trials, termed neoadjuvant therapy, is to treat early stage patients with targeted or immunotherapy before surgical removal of their tumor.
Highlights from the 2019 Scientific Retreat
Over the course of three days, MRA convened over 300 people from across the melanoma research community: patients, doctors, researchers, industry, and government. Participants discussed everything from new treatment approaches such as RNA-based vaccines, strategies to fight back against treatment resistance, and hurdles to testing neo-adjuvant therapies in melanoma.
Building Community While Raising More than $10 Million for Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 15 April 2019 In Allies & Partnerships, Events
Leveraged Finance Fights Melanoma has become an annual event that brings over 1,000 people together from the leveraged finance and private equity community. Cofounder Brendan Dillon shares his own journey with melanoma.
Make Your Sun Safety Habit Stick: La Roche Posay’s My Skin Track UV
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 3 January 2019 In Allies & Partnerships, Prevention
Last month’s arrival of La Roche Posay’s My Skin Track UV may be just what the doctor ordered to help people understand the danger of overexposure to ultraviolet radiation.
Are you #SunSavvy365?
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 4 September 2018 In Allies & Partnerships, Prevention
It’s easy to think of sunscreen when you are lounging by a pool, but did you know that it’s important to protect yourself and those you love every day of the year? That’s why MRA partnered with the Melanoma Action Coalition to create #SunSavvy365, a social media campaign that reminds us to protect our skin whether we are making sand castles or snowmen.
Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC
When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.
We’ve Teamed Up with the American Cancer Society
American Cancer Society and Melanoma Research Alliance have united to fund lifesaving research aimed at reducing side effects and improving outcomes for patients treated with immunotherapy.
American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches to Reduce Immunotherapy Side Effects
As the world marks Melanoma Awareness Month, the American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) selected the first group of scientists to receive newly established research grants to investigate how to reduce rare, but serious, side effects resulting from cancer treatments with checkpoint inhibitors, a type of immunotherapy.
Are Personalized Vaccines Part of a New Combination Approach to Treating Melanoma?
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 29 April 2018 In Allies & Partnerships, Science
Bracing for cold weather and the threat of runny noses and sore throats, millions of Americans are vaccinated for the flu each year. By priming the immune system, the vaccine reduces the risk of catching the flu and, if not successful at preventing it altogether, reduces both the severity and the duration of symptoms. These are ‘one-size-fits-all’ vaccines that are useful for all people. But what if each and every person’s flu, like each person’s melanoma, was unique? You’d need a personalized vaccine that was made and customized for each individual. Dr. Patrick Ott, Clinical Director of the Melanoma Center at the Dana-Farber Cancer Institute and lead researcher on the BJ's Wholesale Club-MRA Team Science Award, is conducting pioneering research to harness the power of personalized vaccines to combat melanoma.